Employer plans that integrate incentivized lifestyle interventions and wellness programs alongside pharmaceutical options could help to manage the risk of reducing GLP-1 coverage
GLP-1 receptor agonists are a class of medications originally developed for type 2 diabetes management
Glutathione is added as an IV push at the end of the NAD+ drip
Since GLP-1s do not pose the specific risks that certain other medications do, taking them does not automatically disqualify you
Int J Mol Sci 2017;18:340
Postmenopausal osteoporosis (type I): After menopause, women experience a sudden drop in estrogen levels, a significant increase in osteoclast activity, accelerated bone resorption, insufficient osteoblast activity, and rapid loss of bone mass (30% -50% loss after 5-10 years of menopause), mainly in the lumbar spine and hip